Skip to main content

Table 2 Clinical responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (FEC regimen vs. PE regimen) during each assessments

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Group

First assessment [cases (%)]

Second assessment [cases (%)]

Third assessment [cases (%)]

FEC arm

151

132

68

 cCR

0 (0.00)

1 (0.76)

3 (4.41)

 cPR

70 (46.36)

76 (57.58)

51 (75.00)

 cSD

67(44.37)

45 (34.09)

13 (19.12)

 cPD

6 (3.97)

7 (5.30)

1 (1.47)

 Missing

8 (5.30)

3 (2.27)

0 (1.47)

PE arm

142

121

49

 cCR

1 (0.70)

6 (4.96)

5 (10.20)

 cPR

97 (68.31)

92 (76.03)

41 (83.67)

 cSD

35 (24.65)

20 (16.53)

2 (4.08)

 cPD

3 (2.11)

3 (2.48)

1 (2.04)

 Missing

6 (4.23)

0 (0.00)

0 (0.00)

  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial response, cSD clinical stable disease, cPD clinical progressive disease